SAVR

Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients

Retrieved on: 
Thursday, April 25, 2024
Education, Patient, Stenosis, Social media, Dizziness, Aortic stenosis, Artificial intelligence, Cardiology, MetroHealth, SAVR, Senior, TAVR, Fatigue, Physician, Surgery, Aortic valve, Chest pain, Cardiovascular disease, Heart, Medical device

LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.

Key Points: 
  • LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.
  • Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly.
  • Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
  • Because treatment continues to increase and evolve, the "Aortic Stenosis Patient Activation Platform", developed by Heart-Valve-Surgery.com with support from Medtronic and a world-renowned team of physicians, will increase awareness and education for aortic stenosis patients.

Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure

Retrieved on: 
Monday, July 31, 2023
Science, Cardiology, Biotechnology, Research, Surgery, General Health, Health, Medical Devices, Male, Structural heart disease, THV, Singapore Space and Technology Ltd, Calcification, SAVR, Viv, ASX, Multimedia, SAP, Aortic stenosis, Patient, Risk, Aortic valve, Health Canada, Medical imaging, Medical device

These patients are at high risk for another surgery and require a minimally invasive treatment option.

Key Points: 
  • These patients are at high risk for another surgery and require a minimally invasive treatment option.
  • Dr. Asgar performed the procedure on an 84-year-old male and implanted a DurAVR™ THV inside the failed surgical aortic valve replacement (SAVR).
  • Additionally, despite this being an incredibly complex case, using Anteris’ ComASUR™ delivery system and deploying the valve was remarkably easy.
  • Eliminating that compromise would be widely beneficial to a rapidly growing population of patients whose current valve is failing.”

SaverOne 2014 Ltd. Announces Pricing of $13 Million Public Offering and Nasdaq Listing

Retrieved on: 
Friday, June 3, 2022
Accident, Company, Research, Marketing, Transport, Form, SAVR, Forward-looking statement, SEC filing, Security (finance), Telephone, ADSS, U.S. Securities and Exchange Commission, ThinkEquity, Nasdaq, Solution, TASE, Sale, GLOBE, Prospectus, ADS, SEC, State Street, Kfar Tikvah

The ADSs and warrants are expected to begin trading on the Nasdaq on June 3, 2022 under the symbols SVRE and SVREW, respectively.

Key Points: 
  • The ADSs and warrants are expected to begin trading on the Nasdaq on June 3, 2022 under the symbols SVRE and SVREW, respectively.
  • The offering is expected to close on June 7, 2022, subject to satisfaction of customary closing conditions.
  • For example, SaverOne is using forward-looking statements when it discusses the expected gross proceeds and the closing of the offering.
  • Forward-looking statements are based on SaverOne 2014 Ltd.s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.

HLT®, Inc. Gains FDA Approval for Two TAVR Clinical Studies

Retrieved on: 
Thursday, March 24, 2022
HLT, Heart, Adrenal insufficiency, Structural heart disease, Sale, TAVR, Geography, Aortic valve, Cardiology, Aortic stenosis, Aorta, SSAS, Aortic insufficiency, CEO, Food, SAVR, Quality of life, Safety, Technology, Food and Drug Administration, Google Images, Physician, Cardiovascular disease, Solution, FDA, Patient, Pharmaceutical industry, Medical imaging

MAPLE GROVE, Minn., March 24, 2022 /PRNewswire/ -- HLT Inc., a Bracco Group Company and a leader in the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, announced today that it has received U.S. Food and Drug Administration (FDA) approval for two clinical studies to assess the performance and safety of its HLT Meridian TAVR Valve System to treat aortic stenosis and aortic regurgitation among high-risk patients suffering from aortic disease.

Key Points: 
  • The HLT Meridian TAVR Valve System is designed to address both patients' and physicians' needs that are unmet by current offerings, and is intended to expand and optimize the clinical and procedural performance."
  • However, TAVR is a minimally invasive way to replace the diseased aortic valve without open heart surgery for this patient population.
  • As stated above, the HLT Meridian TAVR Valve System is not yet cleared/ approved by FDA.
  • The HLTMeridian TAVR Valve System is an investigational device not available for sale in any geography.

InventHelp Inventor Develops Accessory to Store a Partially-Smoked Cigarette (CWC-112)

Retrieved on: 
Wednesday, March 2, 2022
Multimedia, Sale, Ninth Street, SAVR, Smoke, LTR, Tobacco

PITTSBURGH, March 2, 2022 /PRNewswire/ -- ..."I wanted to create an accessory to extinguish and hold a partially-smoked cigarette for later," said an inventor, from Jerome, Ill., "so I invented the SAVR 4 LTR.

Key Points: 
  • PITTSBURGH, March 2, 2022 /PRNewswire/ -- ..."I wanted to create an accessory to extinguish and hold a partially-smoked cigarette for later," said an inventor, from Jerome, Ill., "so I invented the SAVR 4 LTR.
  • My design ensures that the cigarette is preserved in good condition for consumption at a later time."
  • The invention provides a convenient way to store a partially-smoked cigarette.
  • In doing so, it enables the partially-smoked cigarette to be finished later.

Medtronic self-expanding TAVR platform shows excellent longer-term performance at five years in SURTAVI Trial

Retrieved on: 
Friday, November 5, 2021
Mortality, TCT, Medtronic, Longevity, Aortic stenosis, Stroke, Surgery, SAVR, NYSE, Patient, TAVR, Risk, Aortic valve, Medical device, Hydraulic machinery, Pharmaceutical industry

DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Data from the trial showed that the hemodynamic (blood flow) benefits of the Medtronic CoreValve™ and Evolut™ platforms were maintained at five years with an excellent safety profile and stable valve performance in patients with symptomatic, severe aortic stenosis who are at an intermediate risk for open-heart surgery.

Key Points: 
  • The TAVR arm continued to demonstrate durable valve longevity, as evidenced by better mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg; p
  • Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR.
  • "TAVR has revolutionized the treatment of aortic stenosis with more TAVR cases now performed than surgical aortic valve replacement for this disease.
  • For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

Retrieved on: 
Tuesday, August 24, 2021
Gold, Quality of life, Pain, Structural heart disease, U.S. Securities and Exchange Commission, Orientation, Aortic stenosis, Arrhythmia, Physician, Food, Health, Time, Hospital, NYSE, Motion, Food and Drug Administration, Patient, Solution, TAVR, Cardiovascular disease, FDA, SAVR, Coronary, Heart failure, Security (finance), Medical device, Pharmaceutical industry

DUBLIN, Aug. 24, 2021 /PRNewswire/ --Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system.

Key Points: 
  • DUBLIN, Aug. 24, 2021 /PRNewswire/ --Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system.
  • The Evolut FX system incorporates the same supra-annular valve design that has shown hemodynamic performance superior to surgical aortic valve replacement (SAVR) across large-scale, randomized clinical trials.
  • Severe aortic stenosis often reduces a patient's quality of life and limits their daily activities.
  • If left untreated, patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years.

Maven Security Technologies chosen by Walter E. Washington Convention Center to Improve Indoor Air Quality and Reopen with Increased Air and Surface Protection

Retrieved on: 
Thursday, August 12, 2021
Hydrogen, Zero, Fungus, DC, CEO, SAVR, COVID, Convention center, University, Washington Convention Center, Quality control, LLC, Atmosphere, Risk, Virus, Core Security Technologies, MAVEN, Walter, Washington Center, UL (safety organization), Technology, ATC code J07, Smith, DHP, Severe acute respiratory syndrome coronavirus 2, Walter E. Washington Convention Center, UL, Events DC, Bacteria, Safety, Workflow, Solution, Hospital, Food preservation, Risk management, Heating, ventilation, and air conditioning

WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- Maven Security Technologies, an emerging security solutions company in the nation's capital, announced the installation of their Surface & Virus Reduction (SAVR) program in the Walter E. Washington Convention Center.

Key Points: 
  • WASHINGTON, Aug. 12, 2021 /PRNewswire/ -- Maven Security Technologies, an emerging security solutions company in the nation's capital, announced the installation of their Surface & Virus Reduction (SAVR) program in the Walter E. Washington Convention Center.
  • The SAVR solution includes the Synexis BioDefense System, an industry-leading technology that improves indoor air quality.Maven was chosen to provide the air and surface solution for the convention center reopening and deploy SAVR, a comprehensive suite of services that improves indoor air quality.
  • DHP, a patented technology from Synexis, is the centerpiece of Maven's SAVR offering, and in addition to improving air quality, it reduces surface contaminants in occupied spaces.
  • DC is the 1st Convention Center to install Maven's SAVR to fight COVID, other viruses, mold, odor, fungi, bacteria, etc.

Events DC Implements Synexis BioDefense System to Improve Indoor Air Quality at Walter E. Washington Convention Center

Retrieved on: 
Wednesday, August 11, 2021
Hydrogen, Zero, LEED, Washington Center, UL, Industry, MT, EPA, CEO, Health, CITES, Safety, Entertainment, Robert F. Kennedy Memorial Stadium, MAVEN, Risk, Hospital, SAVR, Smith, Carnegie library, Bacteria, DHP, Washington Convention Center, Technology, Nationals Park, Solution, D.C. Armory, National Urban Security Technology Laboratory, Walter, Virus, Convention center, UL (safety organization), Walter E. Washington Convention Center, Event, Biodefense, LLC, Atmosphere, University, Skatepark, Severe acute respiratory syndrome coronavirus 2, Congress, Quality control, RFK, Las Vegas Festival Grounds, Maloof Skate Park, ATC code J07, Mount Vernon Square, Heating, ventilation, and air conditioning, Risk management, Online shopping

WASHINGTON, Aug. 11, 2021 /PRNewswire/ --Today, Events DC, the official convention and sports authority for the District of Columbia, and MAVEN Security Technologies announced the installation of the SynexisBioDefense System, an industry-leading technology to improve indoor air quality at the Walter E. Washington Convention Center.

Key Points: 
  • WASHINGTON, Aug. 11, 2021 /PRNewswire/ --Today, Events DC, the official convention and sports authority for the District of Columbia, and MAVEN Security Technologies announced the installation of the SynexisBioDefense System, an industry-leading technology to improve indoor air quality at the Walter E. Washington Convention Center.
  • "We are proud to partner with MAVEN and Synexis at the Walter E. Washington Convention Center to provide this important technology for improving indoor air quality to the highest standard possible.
  • Events DC and Maven created a custom plan for the Walter E. Washington Convention Center that includes Synexis devices throughout the building including common areas for the general public and employee-only areas.
  • The Walter E. Washington Center becomes the first convention center in the world to install the Synexis BioDefense System.